(VIANEWS) – NORSKE SKOG (NSKOG.OL), J.MARTINS,SGPS (JMT.LS), SANOFI (SAN.PA) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NORSKE SKOG (NSKOG.OL)
32.1% sales growth and 8.63% return on equity
Norske Skog ASA engages in the production and sale of publication and packaging paper products in Norway, rest of Europe, North America, Australasia, Asia, and Africa. It operates in Publication paper Europe, Publication paper Australasia, and Packaging paper segments. The company offers newsprint paper products comprising standard newsprint and other papers; magazine papers, including super calendared and lightweight coated papers; and recycled containerboards. Its products are primarily used in newspapers and magazines, periodicals, catalogues, brochures, advertising materials, inserts/flyers, supplements, free-sheets, directories, direct mail, and books. Norske Skog ASA was founded in 1962 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NORSKE SKOG has a trailing twelve months EPS of kr5.72.
PE Ratio
NORSKE SKOG has a trailing twelve months price to earnings ratio of 5.63. Meaning, the purchaser of the share is investing kr5.63 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.63%.
More news about NORSKE SKOG.
2. J.MARTINS,SGPS (JMT.LS)
9.7% sales growth and 23.95% return on equity
Jerónimo Martins, SGPS, S.A. operates in the food distribution and specialized retail sectors in Portugal, Poland, and Colombia. The company operates through Portugal Retail; Portugal Cash & Carry; Poland Retail; Colombia Retail; and Others, Eliminations and Adjustments segments. It operates food stores under the Biedronka name; and a chain of health and beauty stores under the Hebe banner in Poland, as well as food stores under the Ara name in Colombia. The company also operates supermarkets under the Pingo Doce banner; and cash and carry stores under the Recheio name in Portugal, and under the Bodega del Canasto name in Colombia. In addition, it operates restaurants under the Pingo Doce name; para-pharmacies and petrol stations under Bem-Estar brand; and clothing under Code brand. Further, the company operates coffee shops and kiosks under the Jeronymo name; and chocolates and confectionary retail stores under Hussel name. Additionally, the company engages in human resources top management, real estate management and administration, training, and saline brackish waters aquaculture; wholesale of fruit and vegetables; retail management, consultancy, and logistics activities; purchase and sale of real estate; growing of crops and farming of animals; retail sale of health and beauty products; manufacture of milk and dairy products; rental of air transport equipment; and provision of business portfolio management, financial, and sea passenger water transport services. It is also involved in the trading and distribution of consumer goods; retail and wholesale of non-food products; other business support service activities; and provision of services in the area of wholesale and retail distribution. The company was founded in 1792 and is headquartered in Lisbon, Portugal. Jerónimo Martins, SGPS, S.A. operates as a subsidiary of Sociedade Francisco Manuel Dos Santos, S.G.P.S., S.A.
Earnings Per Share
As for profitability, J.MARTINS,SGPS has a trailing twelve months EPS of €1.04.
PE Ratio
J.MARTINS,SGPS has a trailing twelve months price to earnings ratio of 16.72. Meaning, the purchaser of the share is investing €16.72 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.95%.
Yearly Top and Bottom Value
J.MARTINS,SGPS’s stock is valued at €17.39 at 02:20 EST, way below its 52-week high of €24.02 and way above its 52-week low of €15.20.
Sales Growth
J.MARTINS,SGPS’s sales growth is 8.5% for the current quarter and 9.7% for the next.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 13, 2024, the estimated forward annual dividend rate is 0.66 and the estimated forward annual dividend yield is 3.63%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 22.2% and positive 3% for the next.
More news about J.MARTINS,SGPS.
3. SANOFI (SAN.PA)
7.4% sales growth and 5.82% return on equity
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €4.3.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 21.15. Meaning, the purchaser of the share is investing €21.15 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.82%.
Moving Average
SANOFI’s value is under its 50-day moving average of €100.56 and below its 200-day moving average of €92.72.
Volume
Today’s last reported volume for SANOFI is 1839940 which is 37.38% above its average volume of 1339290.
More news about SANOFI.
4. VISTIN PHARMA (VISTN.OL)
6.6% sales growth and 23.89% return on equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.54.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.86. Meaning, the purchaser of the share is investing kr17.86 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.89%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
Volume
Today’s last reported volume for VISTIN PHARMA is 22168 which is 38.39% below its average volume of 35985.
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr27.50 at 02:20 EST, under its 52-week high of kr28.80 and way above its 52-week low of kr20.60.
More news about VISTIN PHARMA.
5. CREDIT AGRICOLE (ACA.PA)
6.1% sales growth and 7.17% return on equity
Crédit Agricole S.A. provides retail, corporate, insurance, and investment banking products and services in France and internationally. It operates through French Retail Banking – Regional Banks; French Retail Banking – LCL; International Retail Banking; Asset Gathering; Large Customers; and Specialised Financial Services segments. The company offers banking products and services, finance, savings, wealth management, payment, and cash flow management services; consumer finance products; savings/retirement, death and disability/creditor/group, and property and casualty insurance products; investment solutions; and banking and specialized financial services. It also provides investment banking, structured finance, international trade finance, commercial banking, capital market, and syndication services; financing solutions for property and equipment investment and renewal requirements; trade receivable financing and management solutions for corporates; asset servicing solutions for investment products, as well as various asset classes, such as execution, clearing, forex, security lending and borrowing, custody, depositary bank, fund administration, middle-office outsourcing solutions, and fund distribution support and issuer services; and online banking services. The company serves retail customers, corporates, banks and financial institutions, government agencies, and local authorities. Crédit Agricole S.A. was founded in 1894 and is headquartered in Montrouge, France. Crédit Agricole S.A. operates as a subsidiary of SAS Rue La Boetie.
Earnings Per Share
As for profitability, CREDIT AGRICOLE has a trailing twelve months EPS of €1.94.
PE Ratio
CREDIT AGRICOLE has a trailing twelve months price to earnings ratio of 7.12. Meaning, the purchaser of the share is investing €7.12 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.17%.
More news about CREDIT AGRICOLE.
6. VERALLIA (VRLA.PA)
6% sales growth and 29.81% return on equity
Verallia Société Anonyme manufactures and sells glass packaging products for beverages and food products worldwide. It provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. The company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. Verallia Société Anonyme was founded in 1827 and is based in Courbevoie, France.
Earnings Per Share
As for profitability, VERALLIA has a trailing twelve months EPS of €4.01.
PE Ratio
VERALLIA has a trailing twelve months price to earnings ratio of 8.99. Meaning, the purchaser of the share is investing €8.99 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.81%.
Moving Average
VERALLIA’s value is way higher than its 50-day moving average of €26.38 and way higher than its 200-day moving average of €32.42.
Volume
Today’s last reported volume for VERALLIA is 99695 which is 23.8% below its average volume of 130846.
Sales Growth
VERALLIA’s sales growth is 27.9% for the present quarter and 6% for the next.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 14, 2024, the estimated forward annual dividend rate is 2.15 and the estimated forward annual dividend yield is 8.41%.
More news about VERALLIA.
